These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
361 related articles for article (PubMed ID: 27698000)
1. Genomic Approaches to Understanding Response and Resistance to Immunotherapy. Braun DA; Burke KP; Van Allen EM Clin Cancer Res; 2016 Dec; 22(23):5642-5650. PubMed ID: 27698000 [TBL] [Abstract][Full Text] [Related]
2. Immune checkpoints and cancer in the immunogenomics era. Park R; Winnicki M; Liu E; Chu WM Brief Funct Genomics; 2019 Mar; 18(2):133-139. PubMed ID: 30137232 [TBL] [Abstract][Full Text] [Related]
3. The "Tricky Business" of Identifying Mechanisms of Resistance to Anti-PD-1. Wilmott JS; Rizos H; Scolyer RA; Long GV Clin Cancer Res; 2017 Jun; 23(12):2921-2923. PubMed ID: 28468948 [TBL] [Abstract][Full Text] [Related]
4. Gene-expression profiling to predict responsiveness to immunotherapy. Jamieson NB; Maker AV Cancer Gene Ther; 2017 Mar; 24(3):134-140. PubMed ID: 27834354 [TBL] [Abstract][Full Text] [Related]
5. Primary and acquired resistance to PD-1/PD-L1 blockade in cancer treatment. Wang Q; Wu X Int Immunopharmacol; 2017 May; 46():210-219. PubMed ID: 28324831 [TBL] [Abstract][Full Text] [Related]
6. Genomic and molecular alterations associated with primary resistance to immune checkpoint inhibitors. Malhotra J; De S; Nguyen K; Lee P; Villaflor V Cancer Immunol Immunother; 2024 Sep; 73(11):234. PubMed ID: 39271499 [TBL] [Abstract][Full Text] [Related]
8. A Pan-cancer Landscape of Interactions between Solid Tumors and Infiltrating Immune Cell Populations. Tamborero D; Rubio-Perez C; Muiños F; Sabarinathan R; Piulats JM; Muntasell A; Dienstmann R; Lopez-Bigas N; Gonzalez-Perez A Clin Cancer Res; 2018 Aug; 24(15):3717-3728. PubMed ID: 29666300 [No Abstract] [Full Text] [Related]
9. Genomic determinants of cancer immunotherapy. Miao D; Van Allen EM Curr Opin Immunol; 2016 Aug; 41():32-38. PubMed ID: 27254251 [TBL] [Abstract][Full Text] [Related]
10. Mutation patterns in genes encoding interferon signaling and antigen presentation: A pan-cancer survey with implications for the use of immune checkpoint inhibitors. Budczies J; Bockmayr M; Klauschen F; Endris V; Fröhling S; Schirmacher P; Denkert C; Stenzinger A Genes Chromosomes Cancer; 2017 Aug; 56(8):651-659. PubMed ID: 28466543 [TBL] [Abstract][Full Text] [Related]
11. Lessons learned from the blockade of immune checkpoints in cancer immunotherapy. Li X; Shao C; Shi Y; Han W J Hematol Oncol; 2018 Feb; 11(1):31. PubMed ID: 29482595 [TBL] [Abstract][Full Text] [Related]
12. Pan-cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of Response to Checkpoint Blockade. Charoentong P; Finotello F; Angelova M; Mayer C; Efremova M; Rieder D; Hackl H; Trajanoski Z Cell Rep; 2017 Jan; 18(1):248-262. PubMed ID: 28052254 [TBL] [Abstract][Full Text] [Related]
13. Emerging predictors of the response to the blockade of immune checkpoints in cancer therapy. Li X; Song W; Shao C; Shi Y; Han W Cell Mol Immunol; 2019 Jan; 16(1):28-39. PubMed ID: 30002451 [TBL] [Abstract][Full Text] [Related]
14. Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors. Pitt JM; Vétizou M; Daillère R; Roberti MP; Yamazaki T; Routy B; Lepage P; Boneca IG; Chamaillard M; Kroemer G; Zitvogel L Immunity; 2016 Jun; 44(6):1255-69. PubMed ID: 27332730 [TBL] [Abstract][Full Text] [Related]